Abstract:The Present study was a double blind randomized comparative study of Rosuvastatin versus
I.
Introduction:
Dyslipidemias are disorders of lipoprotein metabolism including lipoprotein overproduction and deficiency. They may manifest as one or more of the following: elevated levels of total cholesterol, low density lipoprotein cholesterol(LDL), and triglyceride levels or as decreased levels of high density lipoprotein cholesterol (HDL)
1. Dyslipidemias are closely associated with atherosclerosis and is the major causal factor in the development of ischemic diseases. Ischemic cardiovascular and crebrovascular events are the leading causes of morbidity and mortality
2
. Dyslipidemias are classified into primary (familial hypercholesterolemia) and secondary dyslipidemias (disease states: hypothyroidism, nephritic syndrome, obesity, diabetes, alcoholism and drugs: thiazides, beta blockers, prednisone, progestins, oestrogens and anabolicsteroids)
3 . The benefits of treating hyperlipidemia are that we can reduce the chances of mortality, coronary events like myocardial infarction and stroke 2,4.. Over the past decade, the use of statins or HMG-COA reductase inhibitors for the treatment of hypercholesterolemia has revolutionized physician's ability to slow the progression of CHD
5
.The broad range of significant clinical benefits of statin therapy include a decrease in major coronary events, coronary revascularization, stroke& TIA, death due to CHD, & total mortality 4 .
II. Review of Literature:
Elevated levels of Total cholesterol and triglycerides showed the decrease in HDL-C 5 .According to Lawrence et al, 2007 , there is a strong relation between decrease of LDL-C causes a decreased risk of CHD.
methylglutaryl-COA(HMG-CoA) reductase. Lipids are transported in plasma as lipoproteins, which play an important role in the regulation of lipid transport and lipoprotein metabolism. They are classified on the basis of their densities as chylomicrons, VLDL, IDL,LDL,HDL.
III. Materials and methods:
Subjects participating in the research study were informed for consent as per the Helsinki declaration1977, and clinical history was collected through a structured questionare. Fasting blood samples were collected from Control and study group subjects and suitable anticoagulant was added and plasma was separated and used for further analysis. Total cholesterol was estimated by CHOD-PAP method. Triglycerides were measured by GPO method. HDL-C was measured by Phosphotungstic acid method. Results were obtained from ERBA CHEM 7 Semiautoanalyzer. VLDL was calculated by Friedewald's calculation. Results were expressed as mean ± SD, before and after treatment the parameters were again measured by paired student 't' test. T and p value are calculated and 0.05 are considered as statistically significant. SGOT & SGPT were measured by kinetic mode by semi auto analyser.
Exclusion criteria:
Patients with serious hypersensitivity to statins, severe CHF, Malignancy,hypothyroidism, history with chronic alcoholism, systemic illness, women in breast feeding were excluded from the study.
Inclusion criteria:
Age groups between 35 -70, willing for research trial, were enrolled in the present study .
IV. Results and Discussion:
The mean baseline TC in group A and group B are 220.20±9.4(SD)mg/dl , where P>0.05(i.e P=0.0524) in the mean baseline TC values between the two groups and they are comparable. At the end of study, the mean TC at 12 weeks in group A and group B are 193.39±9(SD)mg/dl and 203.21±7.9(SD)mg/dl respectively. So there is a statistically significant difference at the end of the study where P<0.05(i.e. P=0.001) between two groups. Overall the mean drop in TC in group A and group B are 26.81 mg/dl and 21.76mg/dl. The percentage drop in mean TC in group A and B are 12.17% and 9.6% respectively. The mean baseline TG in group A and group B were 315.52±18.06(SD)mg/dl respectively. There is no significant difference where P>0.05(i.e. P=0.676) in the mean baseline values between the two groups and they are comparable. At the end of the study, the mean TG at 12 wks in group A and group B are 281.64±25.02(S.D)mg/dl and 295.72 ±17.05(S.D)mg/dl respectively. So there is statistically significant difference at the end of the study where P<0.05(i.e. P+0.0136) between the two groups. Overall the mean drop in TG in group A and group B are 31. 23mg/dl and 19.8 mg/dl. The percentage drop in mean TG in group A and B are 9.98% and 6.6% respectively. The mean baseline HDL-C in group A and group B are 28.87±7.492(SD)mg/dl . There wass no significant difference where P> 0.05(i.e. P=0.385) in the mean baseline HDL -C values between the two groups and they are comparable. At the end of the study the mean HDL-C at 12weeks in group A and group B are 33.8±7.874(SD)mg/dl and 29.43±6.669(SD) mg/dl respectively. So there is statistically significant difference at the end of the study where P<0.05( i.e. P=0.0241) between the two groups. Overall the mean increase in HDL-C in group A and group B are 4.93mg/dl and 2.10mg/dl. The percentage drop in mean TC in group A and B are 4% and 2% respectively. The mean baseline LDL-C levels in group A and group B were 134.373±4.828(SD)mg/dl respectively. There is no significant difference where P>0.05(i.e. P=0.2123) in the mean baseline LDL-C values between the two groups and they are comparable. At the end of the study, the mean LDL-C at 12 weeks in group A and group B are 112.05±4.543(SD)mg/dl and 116.49±4.507(SD) mg/dl respectively. So there is statistically significant difference at the end of the study where P<0.05(i.e. P=0.0003) between the two groups. Overall the mean drop in LDL -C in group A and group B are 20. 44 mg/dl and 17.88mg/dl. The percentage drop in mean LDL-C in group A and B are 15.42% and 13.3% respectively.There was no significant difference in the SGOT, group A and B 31 ± 9.2 , 30.9± 9.2,31.91±9.1 respectively and SGPT levels in group A and B before26.3± 9.1after treatment 26.5± 9.0, 26 ± 9.0 respectively with Resuvastatin and Atrovastatin. Both the drugs are equally safe (Tables-1, 2 &3 ).
There was a strong relation between CHD and dyslipidemias Table. 
VI. Conclusion:
The results of this study showed that Rosuvastatin is better than atorvastatin in terms of efficacy. Both drugs are equally tolerated and equally safe.
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